Asmaa Abdel-Aziz

Dr. Asmaa Abdel-Aziz

lecturer of Departments of Pharmacology, Faculty of Medicine, Minia University, 61511 Minia, Egypt.
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YIYasmine Ibrahim
Yasmine Ibrahim
MAMohammed Alorabi
Mohammed Alorabi
WAWalaa Yehia Abdelzaher
Walaa Yehia Abdelzaher
NTNisreen Dm Toni
Nisreen Dm Toni
KTKhaled Thabet
Khaled Thabet
AAAsmaa Abdel-Aziz
Asmaa Abdel-Aziz
Polycystic ovary syndrome (PCOS) is the most common gynaecological endocrine disease that causes anovulatory infertility. The current study aimed to explore the possible role of diacerein (DIA), an IL-1β inhibitor, in treating letrozole-induced PCOS in rats that exhibit the metabolic and endocrinal criteria of PCOS patients. PCOS was induced in female Wistar rats by the oral administration of letrozole (1 mg/kg, per orally, p.o.) for 21 days. Rats were then treated with DIA (25 mg/kg/day, p.o.), DIA (50 mg/kg/day, p.o.), or metformin (2 mg/100 g/day, p.o.) for 14 days after the PCOS induction. PCOS resulted in a significantly higher body weight, ovarian weight, ovarian size, and cysts, as well as an elevation in serum testosterone, LH, insulin, glycemia, and lipid profile levels. All of these effects were significantly reduced by the DIA administration. Additionally, DIA remarkably inhibited the letrozole-induced oxidative stress in the ovaries, muscles, and liver by reducing the upraised levels of malondialdehyde and total nitrite and increasing the suppressed levels of superoxide dismutase and catalase. DIA enhanced the protective proteins Keap-1, Nrf2, and OH-1 levels. Finally, DIA inhibited the elevated mRNA levels of NLRP3 and caspase-1, the up-regulated inflammatory cytokines IL-6, TNF-α, and the IL-1β/NFκB signaling pathway. Our results proved that DIA ameliorates letrozole-induced PCOS through its antioxidant and anti-inflammatory properties.

22 September 2020 in Human & Experimental Toxicology
Verified
Journal Article
Closed access
PDF file
MIMa Ibrahim
Ma Ibrahim
MHMasa Haleem
Masa Haleem
SASA AbdelWahab
SA AbdelWahab
AAAsmaa Abdel-Aziz
Asmaa Abdel-Aziz
Alzheimer disease (AD) is a chronic neurodegenerative disease with multi-pathways pathogenesis. Sildenafil is a selective phosphodiesterase-5 inhibitor with a potential benefit in the treatment of AD. This study investigated the possible mechanisms underlying the effect of sildenafil in AD with emphasis on vascular endothelial growth factor (VEGF), and vascular cell adhesion molecule-1 (VCAM-1). Twenty-four adult male rats were classified into four groups; control group: received vehicles, sildenafil–control: received sildenafil (15 mg/kg/day, p.o.), AD group received Aluminum (25 mg/kg/day, p.o.), AD-treated group: received sildenafil (15 mg/kg/day, p.o.) for 6 weeks. AD was assessed by memory performance test and confirmed by histopathological examination and immunostaining of, neurogenesis marker nestin and α-synuclein. The levels of VEGF-A, VCAM-1, oxidative stress markers and TNF-α in brain tissue were evaluated. AD rats showed histopathological evidences of AD; along with increased latency time in the memory test. There was a decrease in VEGF-A, and an increase in VCAM-1, TNF-α, and oxidative stress markers. Immunohistochemical study showed a significant increase in α-synuclein and a significant decrease in nestin expressions in brain tissues. Sildenafil administration ameliorated the histopathological changes and decreased latency time. Such effect was associated with a decrease in VCAM-1, TNF-α and oxidative stress as well as an increase in VEGF-A. Sildenafil caused a significant increase in nestin and a decrease in α-synuclein immunostaining. These findings suggested a protective effect of sildenafil via modulation of VEGF-A, and VCAM-1.

1 February 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MIMohamed Abdellah Ibrahim
Mohamed Abdellah Ibrahim
WAWalaa Yehia Abdelzaher
Walaa Yehia Abdelzaher
YIYasmine Ibrahim
Yasmine Ibrahim
AAAmira F. Ahmed
Amira F. Ahmed
NWNermeen N. Welson
Nermeen N. Welson
AAAsmaa Abdel-Aziz
Asmaa Abdel-Aziz
Liver ischemia-reperfusion (I/R) injury is an inescapable problem. Diacerein, a chondro-protective drug, has antioxidant and anti-inflammatory effects. Its effect on liver I/R injury has not yet been fully clarified. Therefore, the current study aimed to detect its hepatic protective effect with the explanation of possible underlying mechanisms. Adult male albino rats were assigned to 4 groups: sham group, diacerein pretreated sham group, I/R non-treated group, and I/R diacerein pretreated group. Serum liver enzymes, hepatic tissue oxidative stress parameters, inflammatory biomarkers mainly Toll-like receptors-4 (TLR4), and liver fatty acid binding protein (L-FABP) levels were determined. Histopathological examination of liver tissues and immunohistochemical studies of heat shock protein 70, nuclear factor-kappa B, and Cluster of Differentiation 68 were also done. Diacerein pretreatment has the ability to restore the hepatic I/R damaging effect, proved by the reduction of serum liver enzymes, the decrease of the oxidative stress and hepatic inflammation via down-regulation of TLR4/ NFκ-B signaling pathway together with the restoration of L-FABP level and improvement of the histopathological and immunohistochemical study findings in the hepatic tissue. These results suggested the hepatoprotective effect of diacerein relies on its antioxidant and anti-inflammatory effects reducing TLR4/ NFκ-B signaling pathway.

12 June 2020 in Toxicology Mechanisms and Methods
Verified
Journal Article
Closed access
AAAsmaa Abdel-Aziz
Asmaa Abdel-Aziz
AMAhmed Sayed Mahmoud Mohamed
Ahmed Sayed Mahmoud Mohamed
OAOsama Abdelazem
Osama Abdelazem
AOAhmed Mohamed M. Okasha
Ahmed Mohamed M. Okasha
MKMaha Yehia Kamel
Maha Yehia Kamel
Purpose: Cancer rates have been increased among women of reproductive age nowadays. So, many young female will be exposed to chemotherapeutic agents as cyclophosphamide (CP), carrying the hazards on female fertility. Cilostazol is a selective phosphodiesterase-3 inhibitor drug which exhibits antioxidant, anti-inflammatory and anti-apoptotic activities. We aimed in this study to explore the possible protective effects of cilostazol against CP-induced ovarian damage in female rats. Methods: Cilostazol (10 mg/kg/day) was administered orally for 10 days in presence and absence of CP (150 mg/kg IP single dose) treatment. Serum follicle stimulating hormone (FSH), luteinizing hormone (LH), estrogen (E2) and Anti-mullerian hormone levels (AMH) were determined. Ovarian oxidative stress parameters along with inflammatory biomarkers were measured. 3, 5 cyclic adenosine monophosphate ovarian level (cAMP) was detected. Ovarian histopathological examination and caspase-3 immunohistochemical study were evaluated. Results: CP- treated rats showed a significant increase in serum levels of FSH and LH with decreased serum E2 and AMH levels with an increase in the ovarian inflammatory and oxidative stress biomarkers besides a significant decrease in cAMP ovarian level with an evident histopathological picture of ovarian damage and a high caspase-3 immunoexpression. Cilostazol pretreatment significantly restored the distributed hormonal levels, the oxidative stress and inflammatory biomarkers to their normal levels with marked improvement in histopathological picture of ovarian damage with a significant decrease in caspase-3 immunoexpression. Conclusions: These data suggest that cilostazol protects against CP- induced ovarian damage, which may be related to an increase in cAMP with subsequent anti-inflammatory, antioxidant and anti-apoptotic properties.

29 August 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Mohamed MorsyMohamed Morsy
Mohamed Morsy
AAAsmaa Abdel-Aziz
Asmaa Abdel-Aziz
SHSara Mohammed Naguib Abdel Hafez
Sara Mohammed Naguib Abdel Hafez
Katharigatta VenugopalaKatharigatta Venugopala
Katharigatta Venugopala
ANAnroop B Nair
Anroop B Nair
SASeham A. Abdel-Gaber
Seham A. Abdel-Gaber
Paeonol, a phenolic ingredient in the genus Paeonia, possesses antioxidant and anti-inflammatory effects. Methotrexate (MTX) is a commonly used chemotherapeutic agent; however, its germ cell damage is a critical problem. P-glycoprotein (P-gp), an efflux transporter, is a member of the blood–testis barrier. The present study evaluated the protective effect of paeonol on MTX-induced testicular injury in rats with the exploration of its mechanism and the possible contribution of P-gp in such protection. Testicular weight, serum testosterone, and testicular P-gp levels were measured. Testicular oxidant/antioxidant status was evaluated via determining the levels of malondialdehyde, total nitrite, reduced glutathione, and superoxide dismutase activity. The inflammatory cytokine tumor necrosis factor-alpha (TNF-α) and the apoptotic marker caspase 3 were estimated immunohistochemically. Testicular histopathology and spermatogenesis scores were also examined. MTX caused histopathologically evident testicular damage with decreased testicular weight, testosterone level, and spermatogenesis score, as well as significant increases in oxidative, inflammatory, and apoptotic responses. Paeonol significantly restored testicular weight, testosterone level, spermatogenesis score, and oxidant/antioxidant balance. Moreover, paeonol increased the testicular P-gp level and significantly decreased TNF-α and caspase 3 immunostaining. In conclusion, paeonol offered a protective effect against MTX-induced testicular injury through its antioxidant, anti-inflammatory, and antiapoptotic effects, as well as by increasing testicular P-gp level.

9 June 2020 in Pharmacological Reports
Verified
Journal Article
Closed access
PDF file
AAAsmaa Abdel-Aziz
Asmaa Abdel-Aziz
SASamah Mohammed Mahmoud Abozaid
Samah Mohammed Mahmoud Abozaid
RYRehab Kamal Mohammed Yousef
Rehab Kamal Mohammed Yousef
MMMostafa Mourad Mohammed
Mostafa Mourad Mohammed
HKHanaa Mohamed Khalaf
Hanaa Mohamed Khalaf